Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 121-125    DOI: 10.31083/j.ejgo.2020.01.5072
Case Report Previous articles | Next articles
Glassy cell carcinoma: is surgical treatment with preservation of the uterus a therapeutic option?
N. Habib1, *(), T. Dennis2, G. Centini3, L. Bresson2, F. Narducci2, E. Leblanc2
1 Department of Obstetrics and Gynecology, Beaujon University Hospital, Clichy, France
2 Department of Gynecological Oncology, Oscar Lambert Center, Lille, France
3 Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
Download:  PDF(488KB)  ( 406 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Glassy cell carcinoma (GCC) is a rare and aggressive type of adenoSquamous cervical carcinoma. It affects patients at a younger age compared to the general population of patients with cervical cancer. The five-year survival is inferior to that of the other histological types. The treatment is not standardized. Radiation therapy with concomitant chemotherapy is associated with a better local control and improves oncological results. The authors report here the clinical histories of two patients with an early GCC and a desire of fertility preservation treated with radical trachelectomy with an early recurrence. They conclude that considering the rarity and aggressivity of this histological type, and the lack of evidence in the literature for its management, it would be prudent to consider GCC at an early stage as a contraindication for a radical trachelectomy.
Key words:  Glassy cell carcinoma      Trachelectomy      Cervical cancer      Fertility preservation     
Published:  15 February 2020     
*Corresponding Author(s):  N. HABIB     E-mail:  nassirhabib@hotmail.com

Cite this article: 

N. Habib, T. Dennis, G. Centini, L. Bresson, F. Narducci, E. Leblanc. Glassy cell carcinoma: is surgical treatment with preservation of the uterus a therapeutic option?. European Journal of Gynaecological Oncology, 2020, 41(1): 121-125.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.5072     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/121

[1] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[2] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[3] John P. Micha, Howard D. Epstein, Michael C. Roossin, Randy Bohart, Mark A. Rettenmaier, Bram H. Goldstein. Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 797-801.
[4] Juan Xu, Qingqing Tan, Ting Li. USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 790-796.
[5] Yan qin Zhang, Di Wu, Meng qi Deng, Xiang yu Chang, Jin wei Miao, Yu mei Wu. Individual management of cervical cancer during pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 833-837.
[6] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[7] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[8] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[9] Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.
[10] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[11] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[12] L. Xu, H. Cai, N. Zhu, Bo Zheng. Interleukin-22 derived from cervical cancer-associated fibroblasts accelerates senescence of normal fibroblasts and promotes expression of tumorigenesis-related factors in HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 192-199.
[13] Hong Yan, Chunhua Zhang, Tingting Liu, Jianzhong Liu. Mifepristone regulates the multidrug resistance via miR-758/MEPE of Hela cell lines[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 214-220.
[14] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[15] B. Bárány, R. Póka. Nutritional assessment among patients with cervical cancer and controls[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 23-29.
No Suggested Reading articles found!